{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:16:16Z","timestamp":1792656976090,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014895","name":"Open Philanthropy Project","doi-asserted-by":"publisher","award":["2020-215611"],"award-info":[{"award-number":["2020-215611"]}],"id":[{"id":"10.13039\/100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI149644"],"award-info":[{"award-number":["U01 AI149644"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ebiom.2020.103132","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T05:03:52Z","timestamp":1605935032000},"page":"103132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"special_numbering":"C","title":["Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-5047","authenticated-orcid":false,"given":"Weina","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McCroskery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Slamanig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Amanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Kenneth H.","family":"Dinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2020.103132_bib0001","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"7830","key":"10.1016\/j.ebiom.2020.103132_bib0002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2020.103132_bib0003","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1932","article-title":"Rapid development of an inactivated vaccine candidate for SARS-CoV-2","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"10240","key":"10.1016\/j.ebiom.2020.103132_bib0004","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ebiom.2020.103132_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: status Report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103132_bib0006","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ebiom.2020.103132_bib0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103132_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ebiom.2020.103132_bib0009","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fimmu.2020.00932","article-title":"Potential SARS-CoV-2 pre-immune IgM epitopes","volume":"11","author":"Shivarov","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2020.103132_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ebiom.2020.103132_bib0011","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"issue":"Pt 11","key":"10.1016\/j.ebiom.2020.103132_bib0012","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1099\/0022-1317-80-11-2987","article-title":"Generation of recombinant lentogenic Newcastle disease virus from cDNA","volume":"80","author":"Romer-Oberdorfer","year":"1999","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103132_bib0013","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Fut Microbiol"},{"issue":"11","key":"10.1016\/j.ebiom.2020.103132_bib0014","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/mt.2008.181","article-title":"Recombinant Newcastle disease virus as a vaccine vector for cancer therapy","volume":"16","author":"Vigil","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2020.103132_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","article-title":"Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma","volume":"49","author":"Vijayakumar","year":"2019","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.ebiom.2020.103132_bib0016","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ebiom.2020.103132_bib0017","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S2095-3119(17)61660-5","article-title":"Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels","volume":"16","author":"Liu","year":"2017","journal-title":"J Integr Agric"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103132_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.ebiom.2020.103132_bib0019","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103132_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030016","article-title":"Fifty years of clinical application of newcastle disease virus: time to celebrate!","volume":"4","author":"Schirrmacher","year":"2016","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.ebiom.2020.103132_bib0021","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2020.103132_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-9794-7_9","article-title":"Design and production of newcastle disease virus for intratumoral immunomodulation","volume":"2058","author":"Vijayakumar","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2020.103132_bib0023","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/JVI.79.2.1180-1190.2005","article-title":"Decreased dependence on receptor recognition for the fusion promotion activity of L289A-mutated newcastle disease virus fusion protein correlates with a monoclonal antibody-detected conformational change","volume":"79","author":"Li","year":"2005","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.ebiom.2020.103132_bib0024","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med"},{"issue":"6491","key":"10.1016\/j.ebiom.2020.103132_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ebiom.2020.103132_bib0026","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"issue":"7830","key":"10.1016\/j.ebiom.2020.103132_bib0027","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2020.103132_bib0028","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr Protoc Microbiol"},{"issue":"21","key":"10.1016\/j.ebiom.2020.103132_bib0029","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1073\/pnas.0602566103","article-title":"Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease","volume":"103","author":"Park","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ebiom.2020.103132_bib0030","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2020.103132_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","author":"Li","year":"2020","journal-title":"JAMA"},{"issue":"10236","key":"10.1016\/j.ebiom.2020.103132_bib0032","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2020.103132_bib0033","article-title":"A scalable topical vectored vaccine candidate against SARS-CoV-2","volume":"8","author":"Rohaim","year":"2020","journal-title":"Vaccines (Basel)"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420305089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420305089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:04:39Z","timestamp":1762455879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396420305089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"alternative-id":["S2352396420305089"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.103132","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.26.221861","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.103132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103132"}}